<DOC>
	<DOCNO>NCT00851240</DOCNO>
	<brief_summary>Patients adult-onset rheumatoid arthritis enrol . They dose repeat intravenous dos BTT-1023 placebo . During trial , safety treatment pharmacokinetics BTT-1023 assess . The patient allocation treatment group occur random , actual treatment reveal investigator patient trial .</brief_summary>
	<brief_title>BTT-1023 Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adultonset rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>safety</keyword>
</DOC>